Nextech Invest
Venture capitalZurich · Seed–Late Stage · 3 people tracked
Also known as NEXTECH INVEST LTD.
Find your way into Nextech Invest
686 people in our graph share verified history with the Nextech Invest team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Nextech Invest concentrates on precision medicine, seeking and funding emerging biotechnology companies developing transformative cancer therapies. Operating from Zurich, the firm supports portfolio companies through pivotal stages of scientific validation and value creation, backing biotech innovators on a global scale.
Source: firm website, verified Sep 15, 2026.
Team · 3 people
from the firm's website & public directories
What they invest in
from 61 of 70 portfolio companiesBiotech ×59Healthtech ×28Medical Devices ×20Deep Tech ×14AI & Machine Learning ×10Digital Health ×8Data & Infrastructure ×1Developer Tools ×1
HQs:United States×42Canada×1Germany×1Japan×1
Who they back
founder profiles across 30 portfolio companiesFounding team size:solo founder×172 founders×63 founders×34+ founders×4
Where their founders studiedfrom 30 founders with education data
University of California, Berkeley ×4Massachusetts Institute of Technology ×3Stanford University ×3University of Pennsylvania ×3Columbia University ×2Harvard University ×2Princeton University ×2Stanford University School of Medicine ×2
What their founders studiedfrom 27 founders with field-of-study data
Life Sciences ×17Chemistry ×11Medicine ×4Business & Management ×3Computer Science ×2
Where their founders worked beforefrom 27 founders with career history
Atlas Venture ×2GNF ×2Third Rock Ventures ×2
22 founders hold a PhD · 2 hold an MBA (of 27 with degree data)
Investments · 70 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 32024 · 72023 · 42022 · 12021 · 92020 · 42019 · 22018 · 22017 · 12016 · 22015 · 138 dated
Revolution Medicines develops drug candidates targeting specific genetic mutations in cancer and other serious diseases, advancing them through clinical trials toward regulatory approval and commercialization.
BiotechRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Board seatThilo Schroeder· per SEC Form D
Co-investorsBain Capital Life SciencesForesite CapitalThe Column GroupThird Rock Ventures
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.
BiotechBoston, US
Alan Huang(Executive Officer)inAdam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)
BoardBarbara Weber(Executive Officer, Director)in
Board seatKanishka Pothula· per SEC Form D
Co-investorsForesite CapitalNSG VenturesThird Rock Ventures
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio PartnersWestlake Village BioPartners+1 more
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)in
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)inTim Shannon(Director)in
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsRA CapitalSolasta Ventures+1 more
Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
London
Martin Pulé(Senior Vice President, Founder, Chief Scientific Officer)Christopher Williams(Senior Vice President, Chief Business Development Officer)Edgar Braendle(Executive Officer)inChristopher Vann(Executive Officer)inDavid Brochu(Executive Officer)inChristian Itin(Chief Executive Officer and Director)in
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)
Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)NSG VenturesRA CapitalVersant Ventures+3 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersRA CapitalNEXTECH ONCOLOGY SCSPSignalFire
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investors3E Bioventures CapitalBain Capital Life SciencesRA CapitalCobro Ventures
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.
BiotechHealthtechPhiladelphia, US
Martin Lehr(Founder)inJennifer Minai-Azary(Executive Officer)inAlex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)Philip Kantoff(Director)in
Co-investorsTorrey Pines Investment
Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.
BiotechHealthtechMedical Devices
Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNadim Ahmed(President and Chief Executive Officer)in
Co-investorsForesite CapitalBiotechnology Value FundOrbiMed
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)
BoardTimothy Shannon(Director)inJohn Diekman(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Co-investors5AM VenturesCanaan PartnersBiotechnology Value FundWuXi Healthcare Ventures
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalOUP (Osage University Partners)ARCH Venture
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+5 more
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Taiho Ventures, LLCThe Column GroupOrbiMed
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystRA Capital+7 more
.png)
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Co-investorsCommonweal VenturesEcoR1 CapitalForesite CapitalSoftBank Vision FundCurie.BioGeneral Catalyst+1 more
Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
BiotechLondon
Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)
BoardJames Ede-Golightly(Director)Alistair Gray(Director)
Co-investorsForesite CapitalMC Healthcare VenturesVivo Capital
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in
Co-investorsAlta PartnersBioBritCanaan PartnersNEXTECH ONCOLOGY SCSPRA Capital
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsBrace PharmaCTI Life Sciences Fund L.P.Lumira VenturesWUTIF CapitalAmplitude Venture Capital
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)
BoardPeter Thompson(Director)inCarol Gallagher(Director)in
Board seatAlfred Scheidegger· per SEC Form D
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)5AM VenturesClarus VenturesOrbiMedOsage University Partners+1 more
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Board seatBenjamin Cravatt· per SEC Form D
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersSoftBank Vision FundVersant Ventures
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
C. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)inDavid Goeddel(Director)in
Co-investorsVida VenturesSamsara BioCapitalThe Column Group
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+9 more
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersOrbiMedVida VenturesDigitalis VenturesNVIDIA
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundInkefRA Capital
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
%20copy.jpg)
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesOUP (Osage University Partners)Pfizer Venture InvestmentsvenBio Partners+1 more
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Co-investorsOrbiMedRA CapitalSR One Capital Management
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)in
Co-investorsLux CapitalRA CapitalThe Column Group
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesSanofi VenturesVida VenturesGoldman Sachs+1 more
Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersLongwood FundPathway to CuresAtlas Venture+6 more
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.
BiotechHealthtechCambridge, US
Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in
BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)
Co-investorsF-Prime CapitalForesite CapitalRA Capital
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsRed Tree VentureSamsara BioCapitalAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny VentureThird Rock Ventures
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Co-investorsBerkeley CatalystHemisphere Ventures LLCLifeforce CapitalMission Bay CapitalMission BiocapitalPandect Bioventures+2 more
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.
BiotechHealthtechCambridge, US
Kevin Marks(Founder)in
Co-investorsGV (Google Ventures)Taiho Ventures, LLCAlexandria
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Raptor GroupSamsara BioCapitalBiotechnology Value FundCasdin Capital+1 more
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalInvus+2 more
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.
AI & Machine LearningBiotechDeep TechHealthtech
Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in
Co-investorsNexTech VenturesPfizer VenturesThird Rock VenturesPfizer Venture InvestmentsShangBay Capital LLCAgent Capital
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Prospect Venture PartnersRho Capital PartnersRho VenturesRiverVest Venture Partners+2 more
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)inMaureen E. Hillenmeyer(Executive Officer, Director)inMaureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Co-investorsB3 HoldingSoftBank Vision FundThe Column Group8VCCasdin CapitalTwo Sigma Ventures
Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
BiotechHealthtechNew York, US
Sean Algeo(Executive Officer, Promoter)inMark A. McCamish(Executive Officer, Director)inDavid M. Tanen(Executive Officer, Promoter)
BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in
Co-investorsGV (Google Ventures)Vida VenturesWellington Management
IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases.
BiotechMedical Devices
Co-investorsAndreessen HorowitzRA Capital
ITM is a vertically integrated biotechnology company specializing in precision oncology through radioisotope production and radiopharmaceutical development, with clinical programs advanced through subsidiary Lumara Bio.
BiotechHealthtechMedical Devices
Alexander Pironi(Executive Vice President, Global Head of Radioisotopes)inDr. Konstantin Zhernosekov(Chief Scientific Officer & Managing Director ITM Medical Isotopes & ITM Oncologics)
Co-investorsCapmont
Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.
BiotechCambridge, US
Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRichard Murray(Executive Officer, Director)
BoardRobert Tepper(Director)inCary Pfeffer(Director)inRobert Kamen(Director)in
Co-investorsBoutique Venture PartnersGENERAL INCEPTIONSofinnova VenturesVenture Capital Investment ManagementThird Rock Ventures
A biotechnology company developing cancer therapies for patients with unmet medical needs.
BiotechHealthtech
Co-investorsAtlas VentureF-Prime CapitalEight Roads Ventures
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalAlexandriaLilly Asia VenturesLongwood Fund
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalJanus Henderson InvestorsRA CapitalVenrock Healthcare Capital PartnersViking Global Investors
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Co-investorsEcoR1 CapitalGV (Google Ventures)Vida VenturesBlackRockCommodore CapitalInvus+1 more
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAccess BiotechnologyAtlas VentureForbionRA Capital
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRho Ventures
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman SachsInvus+3 more
BiotechCambridge, US
Richard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)
BoardCary Pfeffer, M.D.(Director)
Co-investorsSofinnova VenturesClal Biotechnology IndustriesThird Rock Ventures
Nextop IO provides a mobile content delivery network with a client-side library for iOS and Android that routes traffic through optimized proxy servers, reducing latency, improving throughput, and lowering data and battery consumption for mobile applications connecting to backend services.
Data & InfrastructureDeveloper ToolsEnterprise Software
Brien Colwell(Founder/CEO)in
Co-investorsY CombinatorAndreessen HorowitzLightspeed Venture PartnersRA Capital
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsCurative VenturesForesite CapitalThe Column GroupVida Ventures
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.
BiotechHealthtechCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)
BoardPeter Thompson(Director)inSteve Winick(Director)Arnold Oronsky(Director)
Co-investorsAvoro Capital AdvisorsOUP (Osage University Partners)RA CapitalOrbiMedOsage University Partners
Sail Biomedicines develops RNA-based medicines using a platform integrating Endless RNA and targeted nanoparticle delivery technology.
AI & Machine LearningBiotechDeep TechCambridge, US
John Mendlein(Executive Chairman)
Co-investorsFlagship PioneeringQuan Capital
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesVida VenturesAbingworth+3 more
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)in
Co-investorsEcoR1 CapitalPontifax Venture CapitalRA CapitalUS Venture Partners
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)inAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRoland Gendron(Chief Business Officer)inMichelle Zhang(Chief Scientific Officer)in
BoardVineeta Agarwala(Director)in
Co-investorsRA CapitalAndreessen HorowitzMagnetic VenturesOMX VenturesAxial VCGV (Google Ventures)+1 more
A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.
BiotechDeep TechMedical DevicesWilmington, US
Liangxing Wu(Executive Officer, Director)inWenqing Yao(Executive Officer, Director)inTing Feng(Director)
BoardReid Huber(Director)in
Co-investorsThe Innovation SpaceThird Rock Ventures
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalLongitude CapitalNexTech VenturesOrbiMedPontifax Venture CapitalRock Springs Capital+1 more
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical Devices
Co-investorsGen CapitalIllinois VenturesThe Column Group
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersBioMedPartnersFrazier Life SciencesFund+OCCIDENTFrazier Healthcare Partners
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investors+ND CapitalARCH Venture PartnersForbionVenrockFast Track InitiativeNovalis LifeSciences+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ambrx BiopharmaArvinasAset TherapeuticsLaronde BioProfound BioTurning Point Therapeutics
Exits · 27
20 IPOs · 7 acquisitions · showing 23Revolution MedicinesNASDAQ: RVMDTango TherapeuticsNASDAQ: TNGXAlumisNASDAQ: ALMSArvinas Holding Co. LLCNASDAQ: ARVNAutolus Therapeutics plcNASDAQ: AUTLBlack Diamond Therapeutics, IncNASDAQ: BDTXBoundless BioNASDAQ: BOLDC4 TherapeuticsNASDAQ: CCCCContext TherapeuticsNASDAQ: CNTXCullinan TherapeuticsNASDAQ: CGEMIdeaya BiosciencesNASDAQ: IDYAKura OncologyNASDAQ: KURAKymera TherapeuticsNASDAQ: KYMRORIC PharmaceuticalsNASDAQ: ORICParabilis MedicinesNASDAQ: PBLSRelayNASDAQ: RLAYSilence TherapeuticsNASDAQ: SLNTYRA BiosciencesNASDAQ: TYRAZymeworksNASDAQ: ZYMEVividion Therapeuticsacq. by BayerPeloton Therapeuticsacq. by MerckSilverback Therapeuticsacq. by ARS PharmaceuticalsTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companiesSilence Therapeutics · investing.com · Sep 16, 2026
Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026
Revolution Medicines · intellectia.ai · Sep 1, 2026
Cullinan Therapeutics · marketbeat.com · Aug 21, 2026
Relay · investing.com · Aug 20, 2026
Kinnate Biopharma · labusinessjournal.com · Aug 17, 2026
TYRA Biosciences · stocktitan.net · Aug 14, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Ideaya Biosciences | 4.6% | $10.00 | May 2019 | $9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Nextech Invest made?
- Nextech Invest has 70 tracked investments, 27 of which have exited, including 6 dated in the last 24 months.
- What stage does Nextech Invest invest at?
- Nextech Invest invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Nextech Invest's typical check size?
- Nextech Invest typically writes checks of $648K – $3.2M.
- What sectors does Nextech Invest focus on?
- Nextech Invest focuses on Biotech, Healthtech, Medical Devices.
- Where is Nextech Invest located?
- Nextech Invest is headquartered in Zurich, CH.
- Does Nextech Invest lead rounds?
- Nextech Invest has led 4 of the 11 rounds where its role is on record.
- Who does Nextech Invest co-invest with?
- Nextech Invest most often shares deals with Foresite Capital, RA Capital, The Column Group, among 99 tracked co-investors.
Co-investors · 26
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
▶14 more co-investors
Andreessen Horowitz5AM VenturesGeneral CatalystF-Prime CapitalOUP (Osage University Partners)Versant VenturesFrazier Healthcare PartnersLux CapitalUS Venture PartnersForbionSignalFire8VCTwo Sigma VenturesNew Leaf Venture Partners
Firms observed investing alongside Nextech Invest, from public investor directories. Shared companies are the overlap with Nextech Invest's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.